Symptomatic DVT · People with cancer with perioperative thromboprophylaxis
LMWH prophylaxis showed no clear difference in symptomatic DVT compared with UFH prophylaxis (moderate certainty).
1 finding from 1 review
Symptomatic DVT measured as asymptomatic DVT · People with cancer with perioperative thromboprophylaxis
LMWH prophylaxis showed no clear difference in symptomatic DVT measured as asymptomatic DVT compared with UFH prophylaxis (low certainty).
1 finding from 1 review
Symptomatic PE · women at increased risk of VTE in the early postpartum period
1 finding from 1 review
Symptomatic DVT · women at increased risk of VTE in the early postpartum period
1 finding from 1 review
Symptomatic PE · pregnant women at increased risk of VTE during pregnancy and the early postnatal period
1 finding from 1 review
Symptomatic DVT · pregnant women at increased risk of VTE during pregnancy and the early postnatal period
1 finding from 1 review
Symptomatic thromboembolic events ( · women at increased risk of VTE in the early postpartum period
1 finding from 1 review
Symptomatic PE · pregnant women at increased risk of VTE during pregnancy and the early postnatal period
It is very uncertain whether antenatal (± postnatal) prophylaxis: heparin (LMWH or UFH) changes symptomatic PE ( compared with no treatment/placebo (very low certainty).
1 finding from 1 review
Symptomatic DVT · pregnant women at increased risk of VTE during pregnancy and the early postnatal period
It is very uncertain whether antenatal (± postnatal) prophylaxis: heparin (LMWH or UFH) changes symptomatic DVT ( compared with no treatment/placebo (very low certainty).
1 finding from 1 review
Symptomatic thromboembolic events ( · pregnant women at increased risk of VTE during pregnancy and the early postnatal period
It is very uncertain whether antenatal (± postnatal) prophylaxis: LMWH changes symptomatic thromboembolic events ( compared with UFH (very low certainty).
1 finding from 1 review
Symptomatic thromboembolic events ( · pregnant women at increased risk of VTE during pregnancy and the early postnatal period
It is very uncertain whether antenatal (± postnatal) prophylaxis: heparin (LMWH or UFH) changes symptomatic thromboembolic events ( compared with no treatment/placebo (very low certainty).
1 finding from 1 review
Symptomatic PE · women giving birth by elective or emergency caesarean (elective or emergency (1 trial), elective cesarean only (1 trial),…
1 finding from 1 review
Symptomatic DVT · women giving birth by elective or emergency caesarean (elective or emergency (1 trial), elective cesarean only (1 trial),…
It is very uncertain whether peripartum/postnatal prophylaxis (caesarean): LMWH changes symptomatic DVT (timing of assessment unclear, within 6 weeks… compared with UFH (very low certainty).
1 finding from 1 review
Symptomatic thromboembolic events ( · women giving birth by elective or emergency caesarean (elective or emergency (1 trial), elective cesarean only (1 trial),…
It is very uncertain whether peripartum/postnatal prophylaxis (caesarean): LMWH changes symptomatic thromboembolic events (timing of assessment unclear,… compared with UFH (very low certainty).
1 finding from 1 review
Symptomatic PE · women giving birth by elective or emergency caesarean (elective only (1 trial), emergency or elective (4 trials))
It is very uncertain whether peripartum/postnatal prophylaxis (caesarean): heparin (LMWH or UFH) changes symptomatic PE (timing of assessment unclear, within 6 weeks… compared with no treatment/placebo (very low certainty).
1 finding from 1 review
Symptomatic DVT · women giving birth by elective or emergency caesarean (elective only (1 trial), emergency or elective (4 trials))
1 finding from 1 review
Symptomatic thromboembolic events ( · women giving birth by elective or emergency caesarean (elective only (1 trial), emergency or elective (4 trials))
It is very uncertain whether peripartum/postnatal prophylaxis (caesarean): heparin (LMWH or UFH) changes symptomatic thromboembolic events (timing of assessment unclear,… compared with no treatment/placebo (very low certainty).
1 finding from 1 review
Symptomatic catheter‐related thrombosis (up to 3 months) · people with cancer with thrombosis prophylaxis and central venous catheters
Low‐molecular‐weight heparin (LMWH) probably leads to lower symptomatic catheter‐related thrombosis (up to 3 months) compared with no LMWH (moderate certainty).
1 finding from 1 review
Symptomatic catheter‐related thrombosis measured as asymptomatic catheter‐related thrombosis (up to 3 months) · people with cancer with thrombosis prophylaxis and central venous catheters
It is very uncertain whether low‐molecular‐weight heparin (LMWH) changes symptomatic catheter‐related thrombosis measured as asymptomatic… compared with no LMWH (very low certainty).
1 finding from 1 review
Symptomatic catheter‐related thrombosis (up to 3 months) · people with cancer with thrombosis prophylaxis and central venous catheters
It is very uncertain whether low‐molecular‐weight heparin (LMWH) changes symptomatic catheter‐related thrombosis (up to 3 months) compared with vitamin K antagonist (VKA) (very low certainty).
1 finding from 1 review